In Vitro Activity of Iclaprim against Respiratory and Bacteremic Isolates of Streptococcus pneumoniaeZHANEL, George G; KARLOWSKY, James A.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 4, pp 1690-1692, issn 0066-4804, 3 p.Article

Pyogenic liver abscess caused by hypermucoviscous Klebsiella pneumoniaeKEYNAN, Yoav; KARLOWSKY, James A; WALUS, Tom et al.Scandinavian journal of infectious diseases. 2007, Vol 39, Num 9, pp 828-830, issn 0036-5548, 3 p.Article

Nitrofurantoin is active against vancomycin-resistant enterococciZHANEL, George G; HOBAN, Daryl J; KARLOWSKY, James A et al.Antimicrobial agents and chemotherapy. 2001, Vol 45, Num 1, pp 324-326, issn 0066-4804Article

In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficileKARLOWSKY, James A; LAING, Nancy M; ZHANEL, George G et al.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 11, pp 4163-4165, issn 0066-4804, 3 p.Article

Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaximeKARLOWSKY, James A; JONES, Mark E; DRAGHI, Deborah C et al.Antimicrobial agents and chemotherapy. 2003, Vol 47, Num 10, pp 3155-3160, issn 0066-4804, 6 p.Article

Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United StatesKARLOWSKY, James A; KELLY, Laurie J; THORNSBERRY, Clyde et al.Antimicrobial agents and chemotherapy. 2002, Vol 46, Num 8, pp 2540-2545, issn 0066-4804Article

AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of ActivityKARLOWSKY, James A; KAPLAN, Nachum; HAFKIN, Barry et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 8, pp 3544-3548, issn 0066-4804, 5 p.Article

Influence of human serum on antifungal pharmacodynamics with Candida albicansZHANEL, George G; SAUNDERS, David G; HOBAN, Daryl J et al.Antimicrobial agents and chemotherapy. 2001, Vol 45, Num 7, pp 2018-2022, issn 0066-4804Article

Multidrug-resistant urinary tract isolates of Escherichia coli : Prevalence and patient demographics in the United States in 2000SAHM, Daniel F; THORNSBERRY, Clyde; MAYFIELD, David C et al.Antimicrobial agents and chemotherapy. 2001, Vol 45, Num 5, pp 1402-1406, issn 0066-4804Article

In Vitro Antimicrobial Resistance of Urinary Escherichia coli Isolates among U.S. Outpatients from 2000 to 2010SANCHEZ, Guillermo V; MASTER, Ronald N; KARLOWSKY, James A et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 4, pp 2181-2183, issn 0066-4804, 3 p.Article

Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005KARLOWSKY, James A; LAGACE-WIENS, Philippe R. S; LOW, Donald E et al.International journal of antimicrobial agents (Print). 2009, Vol 34, Num 4, pp 375-379, issn 0924-8579, 5 p.Article

Genetic relatedness of multidrug-resistant Escherichia coli cultured from geographically diverse outpatient, midstream urine specimensKARLOWSKY, James A; KASLOFF, Sam; NICHOL, Kim A et al.Diagnostic microbiology and infectious disease. 2007, Vol 58, Num 3, pp 283-287, issn 0732-8893, 5 p.Article

Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoinKARLOWSKY, James A; THORNSBERRY, Clyde; JONES, Mark E et al.Clinical infectious diseases. 2003, Vol 36, Num 2, pp 183-187, issn 1058-4838, 5 p.Article

Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001KARLOWSKY, James A; JONES, Mark E; THORNSBERRY, Clyde et al.Antimicrobial agents and chemotherapy. 2003, Vol 47, Num 5, pp 1672-1680, issn 0066-4804, 9 p.Article

In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendationsSAHM, Daniel F; THORNSBERRY, Clyde; MAYFIELD, David C et al.Journal of clinical microbiology (Print). 2002, Vol 40, Num 2, pp 669-674, issn 0095-1137Article

Prevalence of Antimicrobial Resistance among Clinical Isolates of Bacteroides fragilis Group in Canada in 2010-2011: CANWARD Surveillance StudyKARLOWSKY, James A; WALKTY, Andrew J; ADAM, Heather J et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 3, pp 1247-1252, issn 0066-4804, 6 p.Article

Antimicrobial Resistance in Urinary Tract Pathogens in Canada from 2007 to 2009: CANWARD Surveillance StudyKARLOWSKY, James A; LAGACE-WIENS, Philippe R. S; SIMNER, Patricia J et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 7, pp 3169-3175, issn 0066-4804, 7 p.Article

In Vitro Activity of Ceftaroline against Gram-Positive and Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009KARLOWSKY, James A; ADAM, Heather J; DECORBY, Melanie R et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 6, pp 2837-2846, issn 0066-4804, 10 p.Article

In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU StudyWALKTY, Andrew; DECORBY, Melanie; NICHOL, Kim et al.Journal of antimicrobial chemotherapy (Print). 2008, Vol 62, Num 1, pp 206-208, issn 0305-7453, 3 p.Article

Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosaKARLOWSKY, James A; WEAVER, Mellany K; THORNSBERRY, Clyde et al.Journal of clinical microbiology (Print). 2003, Vol 41, Num 7, pp 3339-3343, issn 0095-1137, 5 p.Article

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: Results from the Trust Surveillance Program (1998-2002)KARLOWSKY, James A; THORNSBERRY, Clyde; JONES, Mark E et al.Clinical infectious diseases. 2003, Vol 36, Num 8, pp 963-970, issn 1058-4838, 8 p.Article

Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001KARLOWSKY, James A; DRAGHI, Deborah C; JONES, Mark E et al.Antimicrobial agents and chemotherapy. 2003, Vol 47, Num 5, pp 1681-1688, issn 0066-4804, 8 p.Article

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative BacilliZHANEL, George G; CHUNG, Phillip; HOBAN, Daryl J et al.Drugs (Basel). 2014, Vol 74, Num 1, pp 31-51, issn 0012-6667, 21 p.Article

In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study : CANWARD SYMPOSIUMWALKTY, Andrew; ADAM, Heather J; LAVERDIERE, Michel et al.Diagnostic microbiology and infectious disease. 2011, Vol 69, Num 3, pp 348-355, issn 0732-8893, 8 p.Article

Ceftaroline: A Novel Broad-Spectrum Cephalosporin with Activity against Meticillin-Resistant Staphylococcus aureusZHANEL, George G; SNIEZEK, Grace; SCHWEIZER, Frank et al.Drugs (Basel). 2009, Vol 69, Num 7, pp 809-831, issn 0012-6667, 23 p.Article